Company News
Company News

Company News

July 19, 2017
Piramal Imaging Applauds Interim Results and Reiterates Support of IDEAS Trial in Mild Cognitive Impairment (MCI) and Atypical Dementia presented at AAIC 2017
PDF Read More


June 10, 2017
Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and Molecular Imaging 2017 Annual Meeting
PDF Read More


April 3, 2017
Piramal Imaging and AC Immune present first clinical data for tau PET-imaging tracer PI-2620 at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD)
PDF Read More


February 23, 2017
Piramal Imaging SA and ISOLOGIC Innovative Radiopharmaceuticals Announce Commercial Approval of NeuraCeq™ by Health Canada
PDF Read More


November 1, 2016
Neuraceq Automated Synthesizer Synthera (Neuraceq Synthera) Received Shonin Approval in Japan
PDF Read More


October 5, 2016
The AMYPAD consortium announces the start of a novel research initiative between academic and private research partners to investigate the value of ß-amyloid PET imaging. Piramal Imaging is one of the industry members of this European initiative. For more information visit http://www.amypad.eu


September 6, 2016
Piramal Imaging Announces Strategic Partnership with PET Pharm Biotech for Exclusive Commercialization of Neuraceq™ in Taiwan
PDF Read More


July 22, 2016
New Research on Neuraceq™ (florbetaben F18 injection) Imaging to be Presented at Annual Alzheimer's Association International Conference
PDF Read More


June 7, 2016
Piramal Imaging Presents New Data From Neuraceq™ Research and the Piramal Pipeline at the SNMMI 2016 Annual Meeting
PDF Read More


August 31, 2015
Piramal Imaging Announces Publication of Phase III Neuraceq™ (florbetaben F18) PET Imaging Data in Alzheimer's & Dementia
PDF Read More


July 15, 2015
Piramal Imaging to Present Research on PET Imaging and Influence of Beta-Amyloid Plaques in the Brain at Annual Alzheimer's Association International Conference
PDF Read More


June 08, 2015
Piramal Imaging Presents New Data on Florbetaben in Detecting Beta-amyloid Plaques in Patients with Suspected Alzheimer’s Disease
PDF Read More


June 07, 2015
Piramal Imaging to Present New Research in PET Imaging at Society of Nuclear Medicine and Molecular Imaging 2015 Annual Meeting
PDF Read More


June 04, 2015
Piramal Imaging Announces Strategic Partnership with ISOLOGIC Innovative Radiopharmaceuticals for Exclusive Commercialization of Neuraceq in Canada
PDF Read More


June 02, 2015
Piramal Imaging SA and Ci-Co Healthcare Announce Commercial Approval of Neuraceq™ in Korea
PDF Read More


April 22, 2015
Piramal Imaging is Proud to Support Major New Research Study Assessing the Value of PET Scans in Alzheimer’s Disease and Dementia Diagnosis
PDF Read More


December 1, 2014
Piramal Imaging Taps M2i to Manufacture and Distribute NeuraCeq™ in Ireland
PDF Read More


August 12, 2014
First US Commercial Neuraceq™ Scan for Beta-Amyloid Plaque Imaging Performed at WVU Healthcare
PDF Read More


August 4, 2014
First Site in Europe Begins to Offer Commercial Scans Using Piramal Imaging’s NeuraCeq™ for Beta-Amyloid Plaque Imaging
PDF Read More


June 10, 2014
Research on Piramal Imaging’s NeuraceqTM (florbetaben F18 injection) takes Center Stage at SNMMI
PDF Read More


June 06, 2014
piramal imaging research key topic at society of nuclear medicine and molecular imaging annual meeting
PDF Read More


May 12, 2014
AC Immune and Piramal Imaging announce out-licensing agreement for the development of Tau protein diagnostics in Alzheimer’s disease
PDF Read More


April 30, 2014
NeuraceqTM (florbetaben F18 injection) Data: an Emerging Science Topic at the American Academy of Neurology Annual Meeting in Philadelphia
PDF Read More


March 20, 2014
FDA Approves Piramal Imaging’s NeuraceqTM (florbetaben F18 injection) for PET Imaging of Beta-Amyloid Neuritic Plaques in the Brain
PDF Read More


February 24, 2014
Piramal Imaging Announces EU Approval of NeuraCeqTM (florbetaben 18F)* for PET Imaging of Beta-Amyloid Neuritic Plaque Density in the Brain
PDF Read More


December 20, 2013
CHMP Recommends EU Approval of Piramal Imaging’s NeuraCeqTM (Florbetaben 18F)* for PET Imaging of Neuritic Beta-Amyloid Plaques in the Brain
PDF Read More


November 20, 2013
Piramal Imaging Enters into a Strategic Partnership and Exclusive Licensing Agreement with Ci-Co Healthcare for Commercialization of Florbetaben F18
PDF Read More


October 17, 2013
Piramal Imaging Highlights New Data for Beta-Amyloid Imaging Agent Florbetaben F18 at EANM 2013
PDF Read More


August 19, 2013
Piramal Imaging Provides Comments in Response to the Centers for Medicare and Medicaid Services (CMS) Proposed Coverage Decision for Beta-Amyloid Positron Emission Tomography (PET).
PDF Read More


July 25, 2013
The Centers for Medicare and Medicaid Services (CMS) Draft Decision Could Limit Patient Access to New Technology That May Help in Diagnosing Dementia.
PDF Read More


July 12, 2013
Piramal Imaging Highlights New Data for Florbetaben F18 at AAIC 2013.
PDF Read More


June 6, 2013
Piramal Imaging Highlights New Data for Florbetaben and Other Investigational Radiopharmaceuticals at SNMMI 2013.
PDF Read More


May 7, 2013
Piramal Imaging Welcomes Ana M. Catafau, MD, PhD, as VP, Clinical Research and Development, Neurosciences.
PDF Read More


March 21, 2013
Piramal Imaging announces the acceptance for review of [18F] florbetaben by the FDA and EMA for the visual detection of beta-amyloid in Alzheimer’s disease.
PDF Read More


August 30, 2012
Indian Pharma MNC Piramal investing in German molecular imaging technology.
PDF Read More


April 15, 2012
Piramal Healthcare Limited acquires molecular imaging development portfolio of Bayer Pharma.
PDF Read More